Zhang Tongmei, Li Baolan
Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing 101149, China.
Zhongguo Fei Ai Za Zhi. 2021 Mar 20;24(3):188-195. doi: 10.3779/j.issn.1009-3419.2021.101.04.
With the development of precise medicine, targeted therapy has greatly improved the survival and prognosis of patients in advanced non-small cell lung cancer (NSCLC) with oncogenic drivers. However, no matter which kinds of targeted therapy are inevitable to develop therapeutic resistance, treatment options upon exhaustion of targeted therapies are limited. Immune checkpoint inhibitors (ICIs) can bring long-term survival to some patients with advanced NSCLC because of its unique long tailing effect. More and more studies have shown that ICIs can also benefit NSCLC patients with oncogenic drivers. However, the timing of ICIs intervention, the therapeutic regimen and the predictive biomarkers are actually debated, underscoring the need to explore the potential interest of ICIs in these populations. .
随着精准医学的发展，靶向治疗极大地改善了具有致癌驱动因素的晚期非小细胞肺癌（NSCLC）患者的生存率和预后。然而，无论哪种靶向治疗都不可避免地会产生治疗耐药性，靶向治疗用尽后的治疗选择有限。免疫检查点抑制剂（ICIs）由于其独特的长尾效应，可以为一些晚期NSCLC患者带来长期生存。越来越多的研究表明，ICIs对具有致癌驱动因素的NSCLC患者也有益处。然而，ICIs的干预时机、治疗方案和预测生物标志物实际上仍存在争议，这突出了探索ICIs在这些人群中的潜在价值的必要性。
